Here's a sobering stat: Nearly 3 million people in China are diagnosed with cancer every year, and nearly 2 million people die from the disease annually. Early detection remains the key factor behind whether someone can survive cancer and Concord Medical ( CCM) aims to play a big role. Concord operates more than 100 radiotherapy and diagnostic centers throughout China, with plans to open another 100 during the next five years. Analysts at Brean Murray expect the diagnostic industry to double in size by 2015, driven by wider medical insurance coverage for many middle-class Chinese citizens. Shares look to have 15% to 20% upside if you examine current trends. But shares likely have significantly more upside for patient investors wanting to ride out the company's five-year growth plan. This $7.50 stock could hit $9 in a year, but I look for it to move past $12 in a few years as EPS rises up to $1 by 2013.